Bacterial resistance to antibiotics is a major and fast growing health problem
- Pharma Holdings is addressing the problem with it’s drugs derived from host defence peptides through Structure-activity-relationship studies on Lactoferricin.
- Pharma Holdings’ infection drug candidate degrades the membranes of microorganisms
- Pharma Holdings’ focus is on topical treatment of skin infections and nasal eradication of staphylococci, regardless of resistance
- Pharma Holdings’ infection drug candidate has proven efficacy against a broad range of resistant organisms
- A synthetic protein fragment; a peptidomimetic
- High stability against degradation
- Produced in large scale
- Low cost of synthesis
About Lytixar™ (LTX-109)
LTX-109 is an investigational antimicrobial drug with a novel membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. The drug has a rapid bacteriocidal lytic activity. The drug has been tested in vitro and in vivo models, and has undergone a comprehensive nonclinical safety and toxicology program and been studied in man in a Phase I study, and two phase I/IIa studies. The drug is in development as a treatment for bacterial skin infections, fungal infections and nasal decolonisation of MRSA.